Stevanato Group S.p.A.
STVNHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South. With a market capitalization of $5.60B, it sits in mid-cap territory. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.
Market Cap
$5.60B
Beta
0.75
P/E (TTM)
35.98
P/E (Fwd)
24.40
EPS (TTM)
$0.57
EPS (Fwd)
$0.84
ROE
9.1%
ROA
5.5%
Cash
$79.1M
Total Debt
$445.3M
Free CF
-$104.7M
52W Change
-22.8%
Annual Financials
Cash vs Debt
Where STVN stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, STVN finished 18.95% above its 150-day moving average ($17.41) and 13.17% above its 200-day moving average ($18.30). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is STVN overbought or oversold?
At the September 2, 2026 close, STVN's RSI(14) was 45.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, STVN has $79.1M in cash with $445.3M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$104.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 9.1% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $983.7M (2022) to $1.19B (2025), reflecting a 21% increase over the period.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Stevanato Group S.p.A.'s trajectory.